The effect of orange peel and peppermint extract in coronavirus treatment

The effect of inhalation of orange peel and peppermint extract on reducing the severity of COVID-19 symptoms in patients referred to clinic with a positive result of lung CT scan

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110302005952N2

Enrollment

Registered

2020-12-17

Start date

2020-11-25

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. U07.2 COVID-19, virus not identified

Interventions

Intervention 1: Intervention group: The extract prepared from 14 cc of orange peel essential oil prepared from Ramsar Citrus Cooperative and 2 cc of peppermint essential oil in a 20 cc dropper bottle

Eligibility

Sex/Gender

All

Age

10 Years to No maximum

Inclusion criteria

Inclusion criteria: Pulmonary involvement on CT scan suspected to COVID-19 disease Having suspected clinical signs of COVID-19 disease Informed consent for participating in the study Possibility to visit after 72 hours No need for hospitalization at the time of referral Possibility of inhaling the solution

Exclusion criteria

Exclusion criteria: Hospitalized patient Non-respiratory symptoms suspected to COVID-19 disease

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: 72 hours and one week after the first visit. Method of measurement: Thermometer.;Dyspnea. Timepoint: 72 hours and one week after the first visit. Method of measurement: Non - Mild - Moderate - Severe.;Tachypnea. Timepoint: 72 hours and one week after the first visit. Method of measurement: Inspiration/Minute.;Cough. Timepoint: 72 hours and one week after the first visit. Method of measurement: Non - Mild - Moderate - Severe.;Diarrhea. Timepoint: 72 hours and one week after the first visit. Method of measurement: Non - Mild - Moderate - Severe.;Myalgia. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;Headache. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;Rash. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;Tachycardia. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;Chest Pain. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;SPO2. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;CT Scan Result. Timepoint: One week after the first visit. Method of measurement: Visual Analogue Scale.	—

Measure

Time frame

Fever. Timepoint: 72 hours and one week after the first visit. Method of measurement: Thermometer.;Dyspnea. Timepoint: 72 hours and one week after the first visit. Method of measurement: Non - Mild - Moderate - Severe.;Tachypnea. Timepoint: 72 hours and one week after the first visit. Method of measurement: Inspiration/Minute.;Cough. Timepoint: 72 hours and one week after the first visit. Method of measurement: Non - Mild - Moderate - Severe.;Diarrhea. Timepoint: 72 hours and one week after the first visit. Method of measurement: Non - Mild - Moderate - Severe.;Myalgia. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;Headache. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;Rash. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;Tachycardia. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;Chest Pain. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;SPO2. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.;CT Scan Result. Timepoint: One week after the first visit. Method of measurement: Visual Analogue Scale.

—

Secondary

Measure	Time frame
Increasing the SPO2 with taking medication. Timepoint: 72 hours and one week after the first visit. Method of measurement: Pulse Oximeter.;Shortening the Illness duration. Timepoint: 72 hours and one week after the first visit. Method of measurement: Time Interval.;Reducing Pulmonary Inflammation. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.	—

Measure

Time frame

Increasing the SPO2 with taking medication. Timepoint: 72 hours and one week after the first visit. Method of measurement: Pulse Oximeter.;Shortening the Illness duration. Timepoint: 72 hours and one week after the first visit. Method of measurement: Time Interval.;Reducing Pulmonary Inflammation. Timepoint: 72 hours and one week after the first visit. Method of measurement: Visual Analogue Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadali Ghiasi

Social Security

vahid_ghiaci@yahoo.com+98 38 3225 2341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026